Journal of Thrombosis and Thrombolysis

, Volume 40, Issue 1, pp 1–11 | Cite as

Apixaban and risk of myocardial infarction: meta-analysis of randomized controlled trials

  • Adrienn Tornyos
  • András Vorobcsuk
  • Péter Kupó
  • Dániel Aradi
  • Dániel Kehl
  • András Komócsi


The coagulation system contributes greatly to the evolution of myocardial infarction (MI). Anticoagulation may reduce the occurrence of MI as monotherapy or with concomitant use of aspirin. Activated factor X antagonists (anti-Xa) and direct thrombin inhibitors have promising results in various indications in non-inferiority trials. However, results regarding their cardiovascular safety are heterogeneous. We systematically evaluated the risk of MI and mortality in patients receiving the new-generation oral anti-Xa agent apixaban. Electronic databases were searched to find prospective, randomized, controlled clinical trials (RCT) that evaluated the clinical impact of apixaban. Efficacy measures included frequency of MI, cardiovascular and overall mortality. Outcome parameters of RCTs were pooled with a random-effects model. Between January 2000 and December 2013, 12 RCTs comprising 54,054 patients were identified. Based on the pooled results, there was no increase in the risk of MI in patients treated with apixaban [odds ratio (OR) 0.90; 95 % confidence interval (CI) 0.77–1.05; p = 0.17] compared to different controls. Cardiovascular and overall mortality with apixaban was comparable to the control groups (OR 0.88; 95 % CI 0.72–1.06; p = 0.18, OR 0.89; 95 % CI 0.77–1.03; p = 0.11, respectively). The pooled risk of major bleeding was lower in the apixaban treated groups (OR 0.84; 95 % CI 0.62–1.12; p = 0.23) however this reached significant level only in subgroup analysis of trials with anticoagulant regimes in the control (OR 0.66; 95 % CI 0.51–0.87; p = 0.003). In a broad spectrum of patients and compared to different controls apixaban treatment was not associated with an increase in MI or mortality.


Myocardial infarction Apixaban Meta-analysis 

Supplementary material

11239_2014_1096_MOESM1_ESM.docx (395 kb)
Supplementary material 1 (DOCX 394 kb)
11239_2014_1096_MOESM2_ESM.docx (62 kb)
Supplementary material 2 (DOCX 61 kb)
11239_2014_1096_MOESM3_ESM.docx (91 kb)
Supplementary material 3 (DOCX 90 kb)


  1. 1.
    Perk J, De Backer G, Gohlke H, Graham I, Reiner Ž, Verschuren M, Baigent C (2012) European Guidelines on cardiovascular disease prevention in clinical practice (version 2012). The fifth joint task force of the european society of cardiology and other societies on cardiovascular disease prevention in clinical practice (constituted by representatives of nine societies and by invited experts) developed with the special contribution of the european association for cardiovascular prevention & rehabilitation (EACPR). Eur Heart J 33(13): 1635–1701Google Scholar
  2. 2.
    Andreotti F, Testa L, Biondi-Zoccai GG, Crea F (2006) Aspirin plus warfarin compared to aspirin alone after acute coronary syndromes: an updated and comprehensive meta-analysis of 25,307 patients. Eur Heart J 27:519–526CrossRefPubMedGoogle Scholar
  3. 3.
    Chatterjee S, Sharma A, Uchino K et al (2013) Rivaroxaban and risk of myocardial infarction: insights from a meta-analysis and trial sequential analysis of randomized clinical trials. Coron Artery Dis 24:628–635PubMedGoogle Scholar
  4. 4.
    Uchino K, Hernandez, AV (2012) Dabigatran association with higher risk of acute coronary events: meta-analysis of noninferiority randomized controlled trials. Arch Intern Med 172:397–402CrossRefPubMedGoogle Scholar
  5. 5.
    Moher D, Liberati A, Tetzlaff J, Altman DG (2009) Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. Ann Intern Med 151:264–269CrossRefPubMedGoogle Scholar
  6. 6.
    The Nordic Cochrane Centre: Review Manager (RevMan) (2011)Google Scholar
  7. 7.
    Lassen MR, Gallus A, Raskob GE et al (2010) Apixaban versus enoxaparin for thromboprophylaxis after hip replacement. N Engl J Med 363:2487–2498CrossRefPubMedGoogle Scholar
  8. 8.
    Connolly SJ, Eikelboom J, Joyner C et al (2011) Apixaban in patients with atrial fibrillation. N Engl J Med 364:806–817CrossRefPubMedGoogle Scholar
  9. 9.
    Lassen MR, Raskob GE, Gallus A et al (2010) Apixaban versus enoxaparin for thromboprophylaxis after knee replacement (ADVANCE-2): a randomised double-blind trial. Lancet 375:807–815CrossRefPubMedGoogle Scholar
  10. 10.
    Lassen MR, Raskob GE, Gallus A et al (2009) Apixaban or enoxaparin for thromboprophylaxis after knee replacement. N Engl J Med 361:594–604CrossRefPubMedGoogle Scholar
  11. 11.
    Agnelli G, Buller HR, Cohen A et al (2013) Oral apixaban for the treatment of acute venous thromboembolism. N Engl J Med 369:799–808CrossRefPubMedGoogle Scholar
  12. 12.
    Agnelli G, Buller HR, Cohen A et al (2013) Apixaban for extended treatment of venous thromboembolism. N Engl J Med 368:699–708CrossRefPubMedGoogle Scholar
  13. 13.
    Alexander JH, Lopes RD, James S et al (2011) Apixaban with antiplatelet therapy after acute coronary syndrome. N Engl J Med 365:699–708CrossRefPubMedGoogle Scholar
  14. 14.
    Alexander JH, Becker RC, Bhatt DL et al (2009) Apixaban, an oral, direct, selective factor Xa inhibitor, in combination with antiplatelet therapy after acute coronary syndrome: results of the apixaban for prevention of acute ischemic and safety events (APPRAISE) trial. Circulation 119:2877–2885CrossRefPubMedGoogle Scholar
  15. 15.
    Ogawa S, Shinohara Y, Kanmuri K (2011) Safety and efficacy of the oral direct factor xa inhibitor apixaban in japanese patients with non-valvular atrial fibrillation. The ARISTOTLE-J study. Circ J 75:1852–1859CrossRefPubMedGoogle Scholar
  16. 16.
    Ogawa H, Goto S, Matsuzaki M, Hiro S, Shima D (2013) Randomized, double-blind trial to evaluate the safety of apixaban with antiplatelet therapy after acute coronary syndrome in Japanese patients (APPRAISE-J). Circ J 77:2341–2348CrossRefPubMedGoogle Scholar
  17. 17.
    Granger CB, Alexander JH, McMurray JJ et al (2011) Apixaban versus warfarin in patients with atrial fibrillation. N Engl J Med 365:981–992CrossRefPubMedGoogle Scholar
  18. 18.
    Lassen MR, Davidson BL, Gallus A et al (2007) The efficacy and safety of apixaban, an oral, direct factor Xa inhibitor, as thromboprophylaxis in patients following total knee replacement. J Thromb Haemost 5:2368–2375CrossRefPubMedGoogle Scholar
  19. 19.
    Connolly SJ, Ezekowitz MD, Yusuf S et al (2009) Dabigatran versus warfarin in patients with atrial fibrillation. N Engl J Med 361:1139–1151CrossRefPubMedGoogle Scholar
  20. 20.
    Burness CB, Perry CM (2014) Rivaroxaban: a review of its use in the treatment of deep vein thrombosis or pulmonary embolism and the prevention of recurrent venous thromboembolism. Drugs 74(2):243–262CrossRefPubMedGoogle Scholar
  21. 21.
    Patel MR, Mahaffey KW, Garg J et al (2011) Rivaroxaban versus warfarin in nonvalvular atrial fibrillation. N Engl J Med 365:883–891CrossRefPubMedGoogle Scholar
  22. 22.
    Giugliano RP, Ruff CT, Braunwald E et al (2013) Edoxaban versus warfarin in patients with atrial fibrillation. N Engl J Med 369:2093–2104CrossRefPubMedGoogle Scholar
  23. 23.
    Komocsi A, Vorobcsuk A, Kehl D, Aradi D (2012) Use of new-generation oral anticoagulant agents in patients receiving antiplatelet therapy after an acute coronary syndrome: systematic review and meta-analysis of randomized controlled trials. Arch Intern Med 172:1537–1545CrossRefPubMedGoogle Scholar
  24. 24.
    Hohnloser SH, Oldgren J, Yang S, Wallentin L, Ezekowitz M, Reilly P, Connolly SJ (2012) Myocardial ischemic events in patients with atrial fibrillation treated with dabigatran or warfarin in the RE-LY (randomized evaluation of long-term anticoagulation therapy) trial. Circulation 125:669–676CrossRefPubMedGoogle Scholar
  25. 25.
    Connolly SJ, Ezekowitz MD, Yusuf S, Reilly PA, Wallentin L (2010) Newly identified events in the RE-LY trial. N Engl J Med 363:1875–1876CrossRefPubMedGoogle Scholar
  26. 26.
    Artang R, Rome E, Nielsen JD, Vidaillet HJ (2013) Meta-analysis of randomized controlled trials on risk of myocardial infarction from the use of oral direct thrombin inhibitors. Am J Cardiol 112:1973–1979CrossRefPubMedGoogle Scholar
  27. 27.
    Mega JL, Braunwald E, Wiviott SD et al (2012) Rivaroxaban in patients with a recent acute coronary syndrome. N Engl J Med 366:9–19CrossRefPubMedGoogle Scholar

Copyright information

© Springer Science+Business Media New York 2014

Authors and Affiliations

  • Adrienn Tornyos
    • 1
  • András Vorobcsuk
    • 1
  • Péter Kupó
    • 1
  • Dániel Aradi
    • 2
  • Dániel Kehl
    • 3
  • András Komócsi
    • 1
  1. 1.Department of Interventional Cardiology, Heart InstituteUniversity of PécsPécsHungary
  2. 2.Department of CardiologyHeart CenterBalatonfüredHungary
  3. 3.Department of Statistics and Econometrics, Institute of Applied Studies in Business and Economics, Faculty of Business and EconomicsUniversity of PécsPecsHungary

Personalised recommendations